Skip to main content
. 2021 Aug 30;199(5):467–473. doi: 10.1007/s00408-021-00470-6

Table 1.

General characteristics of the enrolled patients

AE-IPF Control group χ2/t p-value
Number of patients 21 23
Sex (male) 19 (90.5%) 20 (87.0%) χ2 = 0.012 0.914
Age (years), mean ± SD 65.2 ± 6.8 62.4 ± 5.7 t = 1.485 0.145
Duration of IPF (years), mean ± SD 1.2 ± 0.3 1.0 ± 0.5 t = 1.589 0.119
Baseline anti-fibrotic therapya 9 (42.86%) 12 (52.17%) χ2 = 0.100 0.752

aBaseline anti-fibrotic therapy included pirfenidone and nintedanib